Skip to main content

Table 1 Baseline characteristics based on the 55 investigated SLE patients

From: Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Characteristic 
Female participants, n (%)50 (90.9)
Ethnicity
 Caucasian, n (%)52 (94.5)
 African/African American, n (%)3 (5.5)
Age (years), median (IQR)41.2 (30.6–50.4)
SLE disease duration (years), median (IQR)7.8 (4.3–14.2)
SLEDAI-2K, median (IQR)8.0 (4.0–14.0)
C3 (g/L), median (IQR)0.81 (0.62–1.02)
C4 (g/L), median (IQR)0.11 (0.06–0.19)
Number of DMARDs tested until baseline*, median (IQR)2 (1–3)
Number of DMARDs at baseline*, median (IQR)1 (0–1)
 Azathioprine, n (%)18 (32.7)
 Mycophenolate mofetil/sodium, n (%)10 (18.2)
 Methotrexate, n (%)8 (14.5)
 Cyclosporine, n (%)2 (3.6)
Antimalarial agents at baseline, n (%)41 (74.5)
Prednisone equivalent dose at baseline (mg/day), median (IQR)10.0 (8.4–12.9)
Reason for belimumab
 Mucocutaneous manifestations, n (%)26 (47.3)
 Musculoskeletal manifestations, n (%)25 (45.5)
 Hematological manifestations, n (%)10 (18.2)
 Lupus nephritis, n (%)7 (12.7)
 Neuropsychiatric SLE, n (%)4 (7.3)
 Serositis, n (%)3 (5.5)
 Constitutional symptoms#, n (%)2 (3.6)
  1. *Excluding antimalarial agents
  2. Mycophenolate mofetil (n = 9) and mycophenolate sodium (n = 1)
  3. #Fatigue
  4. SLE systemic lupus erythematosus, SLEDAI-2K systemic lupus erythematosus disease activity index 2000, DMARDs disease-modifying antirheumatic drugs, IQR interquartile range